Skip to main content

Table 1 Clinical parameters of recruited subjects

From: Simultaneous identification of GSTP1 Ile105→Val105 and Ala114→Val114 substitutions using an amplification refractory mutation systempolymerase chain reactionassay: studies in patients with asthma

 

FEV1 >80% predicted*

 
 

BHR negative

BHR positive

BHR positive

 
 

(PC20 >16 mg/ml; group 1)

(PC20 8–16 mg/ml; group 2)

(PC20 0.03–8 mg/ml; group3)

FEV1≤80% predicted* (group 4)

Parameters

    

n (%)

58 (33.9)

15 (8.8)

51 (29.8)

47 (27.5)

Mean age ± SD (years)

37.0 ± 11.9

29.3 ± 6.8

33.0 ± 11.1

41.4 ± 11.0

Males (n [%])

18 (31.0)

4 (26.7)

13 (25.5)

16 (34.0)

Females (n [%])

40 (69.0)

11 (73.3)

38 (74.5)

31 (66.0)

Skin test negative (n [%])

32 (55.2)

7 (46.7)

12 (23.5)

7 (14.9)

Skin test positive (n [%])

26 (44.8)

8 (53.3)

39 (79.5)

40 (85.1)

IgE ≤100 IU/ml* (n [%])

38 (71.7)

10 (83.3)

21 (46.7)

16 (40.0)

IgE >100 IU/ml* (n [%])

15 (28.3)

2 (16.9)

24 (53.3)

24 (60.0)

  1. *In some patients we were unable to obtain a complete data set. Some individuals were unwilling to undertake a metacholine challenge test, whereas others did not wish to donate a blood sample (in this case DNA was isolated from a mouthwash sample). Mean FEV1 = 67% predicted (min = 45%, max = 78%).